US/UK/Canada

Share

Contacts

  • Probi
    Ideongatan 1A, 223 70 Lund
    +46(0)46-286 89 20
    https://www.probi.com
  • Anita Johansen

    Interim CEO & VP R&D


    +46 46 286 89 20
  • Basudha Bhattarai Johansson

    VP HR & Sustainability


    +46 46 286 89 20

    • Quotes

    A lot of virus and bacteria enter the body through the mucous membranes, where a majority of our immune system is located. Therefore, we believe that probiotics can play a vital role as delivery carrier.
    Professor Magnus Johansson
    This joint venture is an important step in our commercial efforts to address new and attractive market niches. Even in these turbulent times we see great opportunities to jointly build a successful business, based on our longstanding relationship and confidence in our respective abilities to create scientific and commercial success.
    Tom Rönnlund, CEO Probi
    “We are very excited about the results showing an opportunity to delay the progression of bone loss by using our probiotics in this healthy population, which potentially may lead to a reduced risk for osteoporosis.”
    Ole Søgaard Andersen, CEO of Probi
    We are very happy to initiate this development program together with a strong global partner in OTC. By combining Probi´s probiotic expertise with the pharma company's development resources and regulatory expertise, we will form a very strong team moving forward together.”
    Ole Søgaard Andersen CEO of Probi
    “We are proud to conclude that our largest clinical trial so far has successfully confirmed earlier clinical results. Interestingly, in subjects that did not experience any viral infection during the study period, there was an activation of the immune system measured already after 2 weeks of Probi Defendum® intake, indicating an alert and resilient immune system.”
    Peter Nählstedt, CEO Probi AB
    “It is extremely exciting to launch the new probiotic line - Probi Select™. Through the integration of Nutraceutix, Probi has established a complete probiotic offering with the Probi Premium, Probi Select and Probi LiveBac ranges. Probi is now a true “One stop shop” for any consumer goods company wanting to drive their position in the probiotic market”
    Niklas Bjärum, President Probi USA and Global Sales & Marketing Probi Group.
    I am very excited about this transforming acquisition. Nutraceutix is an excellent match for us. Probi and Nutraceutix have complementary business models, limited customer overlap and share strong entrepreneurial values. The acquision creates a strong platform to continue the growth story in the US and in the global market.
    Peter Nählstedt
    ”There has been strong growth in the North American and Asian probiotic markets the past few years. We now see a growing interest in Europe too, and our new distribution agreements clearly reflect this positive trend
    Niklas Bjärum, Vice President of Marketing & Sales
    Pick a time period -
    Tags ( Active)

    Probi expands its probiotic offering with two new areas: Sports & Active Nutrition and Pets

    Global biotics solutions company Probi has expanded its portfolio with two new areas: Sports & Active Nutrition by Probi® and Pets by Probi®. These launches mark a significant step towards Probi’s vision to improve lives through the science of biotics, delivering clinically documented solutions that enhance health for humans – and now also their pets. With more consumers seeking natural and science-backed ways to boost energy, endurance and recovery, the active nutrition market is on the rise. Sales of performance nutrition grew by 15.4 percent* across U.S. retail channels in 2024, and

    Probi marks Sustainability Day with 44% cut in carbon emissions since 2019

    PRESS RELEASE OCTOBER 29, 2025   As the world observes the annual Sustainability Day, Probi highlights its progress in the fight against climate change with a 44% reduction in carbon emissions compared to its 2019 baseline, as well as facilities now running on 100% renewable energy. World Sustainability Day is celebrated every year on the last Wednesday of October; this year it falls on the 29th. It’s an initiative to raise awareness about sustainability and the importance of committing to practices that protect the environment for future generations. “At Probi, our

    Updated BLIS agreement strengthens Probi’s portfolio with new exclusivity for oral health probiotic strains in both humans and pets

    Probi has reinforced its partnership with BLIS Technologies (BLIS®) through an updated agreement, granting Probi exclusive distribution rights for the probiotic strains BLIS K12™ and BLIS M18™ in the US, Canada, and select EMEA markets for both human and pet health. This positions Probi at the forefront of oral health innovation for a broader range of customers. Probi and BLIS Technologies have strengthened their long-term strategic partnership through a renewed agreement that extends Probi's exclusivity for the manufacture and distribution of BLIS probiotic strains for human oral health

    Probi wins third NutraIngredients award for women’s health - with recognition now extending to Asia

    Probi’s solution for iron absorption is on a winning streak, earning global acclaim for addressing a widespread health need. The recognition across three distinct regions during 2025 underlines the worldwide need for effective, well-tolerated iron supplementation. Probi’s innovative concept for enhancing iron absorption, a microbiome-based solution targeting a critical health issue particularly affecting women, has won the 2025 NutraIngredients-Asia Award in the category Innovation in Women’s Health. The award was presented during a live ceremony in Bangkok on the 17th of September.

    Women’s Health by Probi wins NutraIngredients-USA Award for Innovation in Women’s Health

    Probi is proud to announce that Women’s Health by Probi: Iron Absorption has been named the winner of the 2025 NutraIngredients-USA Award in the Innovation in Women’s Health category. The award was presented during a ceremony in Chicago, recognizing excellence in science-backed innovation across the health and nutrition industry.The judges praised the product’s novelty and broad relevance, stating: “There hasn't been a lot of novelty or innovation in the iron space, so we were delighted to see an innovative offering with an interesting mechanism of action and such a large reach. We also

    Probi Female wins prestigious NutraIngredients Award 2025 for innovation in women’s health

    Probi is proud to announce that Probi[®] Female has won the NutraIngredients Award 2025 in the category Innovation in Women’s Health. The award was presented live at Vitafoods Europe in Barcelona, celebrating scientific excellence and commercial impact in the global health and nutrition industry. “We’re incredibly proud and truly honored,” says Martina Pettersson, Global Marketing Director at Probi. “This recognition underscores both the strength of the product and the importance of science-driven innovation in women’s health. The response has been outstanding, and this award marks an

    First-of-its-kind: Nomura Dairy and Probi introduce probiotic-enhanced carrot juice to Japan

    Global probiotic leader Probi[®] has partnered with Nomura Dairy Products to bring its flagship strain to Japan in a groundbreaking new product: the country’s first fermented drink fortified with LP299V[®]. This innovative beverage combines the natural benefits of carrot juice with the proven digestive support of LP299V—marking a major milestone in Probi’s growth in Asia and delivering science-backed gut health to Japanese consumers. Nomura Dairy Products Co., Ltd, a manufacturer specializing in intestinal health and an innovator in functional beverage development, has officially

    Delisting of Probi

    Nasdaq Stockholm has decided that Probi AB will be delisted from Nasdaq Stockholm. The last day of trading in the share will be on 12 February 2025. For further information, please contact: Anita Johansen, CEO, Probi, Telephone: +46 (0)723 99 48 21, anita.johansen@probi.com ABOUT PROBI Probi® is a global biotics solutions company, focused on researching, manufacturing, and delivering biotics for supplements and functional food. Founded on science, and together with customers and research partners, Probi is striving towards a future in which as many people as possible can take

    Notice of Extraordinary General Meeting in Probi AB (publ)

    Symrise AG (“Symrise”) has declared its public tender offer to the shareholders of Probi AB (publ) (“Probi”) unconditional and controls more than 90 per cent of the total number of shares and votes in Probi. Against this background, the shareholders of Probi reg. no. 556417-7540, are hereby officially convened to an Extraordinary General Meeting (“EGM”) which will be held on 13 February 2025 at 15:00 at Probi HQ, Ideongatan 1A, Lund, Sweden. The Board of Directors has decided that shareholders shall be able to exercise their voting rights at the EGM also by postal voting in accordance

    Probi applies for delisting and convenes an Extraordinary General Meeting

    On 16 January 2025, Symrise AG (“Symrise”) has declared the public offer for all shares in Probi AB (“Probi” or the “Company”) unconditional. Symrise controls more than 90 per cent of the shares in Probi and has communicated its initiation of a forced redemption (squeeze-out) of the remaining shares in the Company. Further to the initiation of the squeeze-out process, the Board of Probi has today resolved to apply for delisting of the Company’s shares from Nasdaq Stockholm. The last day of trading in the Company’s shares on Nasdaq Stockholm will be announced as soon as the Company has

    Statement from the independent bid committee of Probi in relation to the public takeover offer by Symrise

    The independent bid committee of Probi AB (publ) (“Probi” or the “Company”) unanimously recommends the shareholders of Probi to accept the cash-based public takeover offer submitted by Symrise AG (“Symrise”) on 20 November 2024.Background This statement is made by the independent bid committee of Probi pursuant to Nasdaq Stockholm’s Takeover Rules (the “Takeover Rules”). On 20 November 2024, Probi’s principal shareholder and parent company Symrise announced that Symrise is making a public takeover offer to the shareholders of Probi for SEK 350 per Probi share (the “Offer”). Probi’s

    Probi’s Board comments on Symrise’s public takeover offer

    On this day 20 November 2024, Probi AB’s (“Probi”) principal shareholder and parent company Symrise AG (“Symrise”) has announced that Symrise is making a public takeover offer to the shareholders of Probi for SEK 350 per Probi share (the “Offer”). The acceptance period for the Offer is expected to commence on 18 December 2024 and end on or about 15 January 2025. For further information, please refer to Symrise’s press release, www.symrise.com/de/probi 

    Probi CFO departure

    Effective today, and by mutual agreement, Per Lindblad will leave his position as CFO at Probi AB (publ). Ulf Sköld has been appointed as interim CFO and will take over immediately, until a permanent successor has been appointed. Ulf has extensive experience as CFO from different industries such as packaging and food industry. Ulf most recently held interim CFO role at Lime Technologies. Ulf holds degree in Economics from Lund University.  "Per has been an engaged member of the management team during a year of transition, and I want to take the opportunity to thank him for the work he

    Probi Launches Clinically-Supported Probiotic Solution for Metabolic Health at SupplySide West 2024

    With 88 percent of U.S. adults being metabolically unhealthy[1] and over 1.9 billion adults classified as overweight worldwide[2], the need for effective metabolic health solutions is acute. To tackle one of the most critical health issues of our time, Probi is unveiling a new product concept.Metabolic health, cardiovascular support, and weight management are all key areas addressed by Metabolic Health by Probi®, the latest innovation from Probi which will be unveiled at SupplySide West 2024 during October 28–31. “Our aim is to help people take control of their microbiome, their gut, and

    Q3 2024: Tangible improvement in operations

    Important events during the third quarter · Net sales in Q3 amounted to SEK 143.7 m, corresponding to a decrease of 7.9% compared to last year (-5.1% adjusted for currency effects). · The EBITDA margin was 20.1%, corresponding to an increase of 2.0 %-points compared to last year. · Probi successfully implemented a new global ERP system, streamlining operations and enhancing efficiency across key business functions. · A new study suggests that consuming Probi's proprietary probiotic strain HEAL9[®] may serve as a potential therapeutic option for mitigating mild cognitive

    Presentation of Probi’s Q3 Report 2024

    Probi’s report for the third quarter 2024 will be published on Tuesday, 22 October at 8.00 a.m. CET. In conjunction with this, analysts, investors and media are invited to an audiocast telephone conference on the same day at 10.00 a.m., where CEO Anita Johansen and CFO Per Lindblad will present and comment on the report. The presentation and presentation material can be obtained via www.probi.com or https://ir.financialhearings.com/probi-q3-report-2024 If you wish to participate via webcast, please use the link below. Via the webcast you are able to ask written questions. https://ir.

    Probi partners with Global BHP BrainTrust and the FINGERS Brain Health Institute to counteract dementia

    Probi today announces a research collaboration with the Global BHP BrainTrust and FINGERS Brain Health Institute (FBHI) aimed at reducing dementia risk in women, who account for two-thirds of Alzheimer’s cases. The collaboration is part of the planned FINGERS Plus for Women study."We are thrilled to be part of the FINGERS Plus for Women initiative. This collaboration represents a significant step forward in our commitment to advancing brain health and improving everyday life for people worldwide. By combining our expertise in probiotics with the innovative research approach of the Global

    Nordic launch of Probi Sense – a unique dietary supplement for the mental capacity

    Today, on World Mental Health Day, Probi launches Probi Sense, a brand-new probiotic food supplement reducing stress and improving mental well-being. The new product will shortly become available directly to consumers through pharmacies and selected retailers across Sweden, Denmark and Norway.Probi Sense contains Probi's unique and well-documented lactic acid bacteria strain Lactiplantibacillus plantarum HEAL9 (HEAL9[®]), as well as the minerals zinc, iodine and magnesium. The product, underpinned by four clinical studies demonstrating its positive effects, is designed to support mental

    New study strengthens Probi[ ][®]s L. plantarum HEAL9[®] strain in cognitive function

    A new study published in the journal Food & Function shows that Probi’s proprietary probiotic strain LPHEAL9 reduced cognitive impairment and inflammation in both the gut and brain in a mice model of Alzheimer's disease (AD). These findings confirm LPHEAL9's role in Gut-Brain health and offer hope for future preventative measures in the early stages of Alzheimer's.This is the fifth study highlighting the effects of the probiotic strain Lactiplantibacillus plantarum HEAL9 on the Gut-Brain axis, adding valuable insights into its potential for supporting everyday health. Conducted in

    Q2 2024: Significant progress on strategic initiatives

    Important events during the second quarter · Net sales in Q2 amounted to SEK 178.9 m, corresponding to an increase of 25% compared to last year (23% adjusted for currency effects). · The EBITDA margin was 19%, corresponding to an increase of 10 percentage points compared to last year. · Probi and ProViva celebrated 30 years of collaboration, highlighting the success with ProViva's popular probiotic drinks containing Lp299v[®]. · Probi strengthened its presence in APAC by launching China Innovation Day, a customer-oriented event focused on fostering collaborations in the

    Presentation of Probi’s Q2 Report 2024

    Probi’s report for the second quarter 2024 will be published on Tuesday, 16 July at 8.00 a.m. CET. In conjunction with this, analysts, investors and media are invited to an audiocast telephone conference on the same day at 10.00 a.m., where CEO Anita Johansen and CFO Per Lindblad will present and comment on the report. The presentation and presentation material can be obtained via www.probi.com or https://ir.financialhearings.com/probi-q2-report-2024 

    Probi® launches at Matas, Denmark's leading health retailer

    As the Swedish market leader in probiotic supplements, Probi AB is proud to announce that our products are now also available in Denmark, at the country's leading health-oriented retail chain, Matas. Through this collaboration, we can offer our scientifically proven probiotic solutions to a wider audience and strengthen our commitment to improving people's health and well-being in the Nordic region.In recent years, consumers' views on health have changed significantly, with an increased focus on preventive health measures and overall well-being. Interest in gut health is growing, driven by

    There are no items matching the current filter
    There are no more items matching the current filter
    Back to top

    Subscribe

    Media